XLM is up 0.04 percent in the last 24 Hours. The transaction took place at 04:13:26 UTC on Thursday, 20

The post has appeared first on thenewscrypto.com

Are we old enough now to consider original PlayStation graphics as retro? Also, when you look back at those graphics now, they’re a little weird aren’t they? Fatum Betula leans heavily into this and looks like a really unique and atmospheric game. Best of all, Fatum Betula is available to download today for Xbox.

The post Experience the outright weird world of Fatum Betula appeared first on TheXboxHub.

This article was published as a part of the Data Science Blogathon. Hello, I hope you are fine. I want to welcome you to a beautiful article on creating a REST API using Flask. In one of our previous articles, we have learned the basics of Flask and how to set it. We have made one […]

The post Complete Guide on Rest API with Python and Flask appeared first on Analytics Vidhya.

Are you looking for a trustworthy bitcoin and crypto news site? Click here to find out our top picks, based on user reviews and social following.

The post Best Bitcoin and Cryptocurrency News Sites 2022 appeared first on Bitcoin Market Journal.

The Pennsylvania Gaming Control Board (PGCB) voted at its monthly meeting Wednesday to banish four people from all of the commonwealth’s casinos after they were caught gambling while leaving one or more children unattended. They were among 10 people PGCB commissioners voted to place on its Involuntary Exclusion List at the meeting. The list is […]

The post Pennsylvania Bans Four from Casinos for Leaving Kids Unattended to Place Bets appeared first on Casino.org.

TOKYO, Jan 20, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine. The pivotal study evaluated the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting.

The publication includes previously reported data that was first presented in an oral plenary session at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.(1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Objective response rate (ORR) data and additional detailed efficacy and safety data, including subgroup analyses, are also featured in the publication.

"While rates of endometrial carcinoma continue to rise globally, patients with advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy," said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients."

"The Phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. share in addressing the unmet needs of people living with difficult-to-treat cancers, including advanced endometrial carcinoma," said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology Business Group at Eisai Inc. "The publication of this study in the New England Journal of Medicine reflects the importance of our joint research in exploring the potential of the LENVIMA plus KEYTRUDA combination."

The publication contains results for the all-comer population, including the mismatch repair deficient (dMMR) patient population for which LENVIMA plus KEYTRUDA is not approved in the U.S.

Based on the results from the Phase 3 Study 309/KEYNOTE-775 trial, LENVIMA plus KEYTRUDA has been approved in the U.S. for patients with advanced endometrial carcinoma that is not microsatellite instability-high or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in more than 10 different tumor types across more than 20 clinical trials.

(1) Eisai co., Ltd. Home page. "LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study". https://www.eisai.com/news/2021/news202116.html

Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
Investor Relations:
+81-(0) 70-8688-9685

Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Relations
Melissa Moody: +1-(215) 407-3536
Nikki Sullivan: +1-(718) 644-0730
Investor Relations
Peter Dannenbaum: +1- (908) 740-1037
Raychel Kruper: +1-(908) 740- 2107

For more information, visit https://www.eisai.com/news/2022/news202207.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.

Program developed in partnership with National Institute of Innovation and Technology and Hennepin Technical College BLOOMINGTON, Minn.–(BUSINESS WIRE)–SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced the launch of an apprenticeship program at its Bloomington, Minnesota facility, designed with a combination of on-the-job training and formal education, and based on industry and academic-approved […]

The post SkyWater Launches Apprenticeship Program to Support Employee Career Growth and Domestic Semiconductor Workforce Development appeared first on Fintech News.

  Curaleaf Holdings, Inc. (CSE: CURA /OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, today announced the completion of its previously announced acquisition of Bloom Dispensaries (“Bloom”), a vertically integrated, single state cannabis operator in Arizona (the “Transaction”). With the close of the Transaction, Curaleaf’s retail footprint has reached 13 dispensaries […]

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, announced the submission of public comments to the Food and Drug Administration concerning its proposed rule to create a new regulatory category of over the counter hearing aids.

Zynex, Inc. today announced it is adding post-operative and OA (Osteoarthritis) knee braces to its line of pain and rehabilitation products.

From Software's next outing releases February 25, make sure you have it day 1.

Many customers are modernizing their data architecture using Amazon Redshift to enable access to all their data from a central data location. They are looking for a simpler, scalable, and centralized way to define and enforce access policies on their data lakes on Amazon Simple Storage Service (Amazon S3). They want access policies to allow […]